Characterization and in vitro permeation study of microemulsions and liquid crystalline systems containing the anticholinesterase alkaloidal extract from Tabernaemontana divaricata

International Journal of Pharmaceutics

Volumn 452, Issue 1-2, 2013, Pages 201-210

  Chaiyana, Wantida ^a   Rades, Thomas ^b   Okonogi, Siriporn ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Alkaloid; Anticholinesterase activity; Liquid crystalline; Microemulsion; Tabernaemontana divaricata

Indexed keywords

ACETYLCHOLINESTERASE; ALKALOID; CHOLINESTERASE INHIBITOR;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG PENETRATION; ENZYME INHIBITION; IN VITRO STUDY; LIQUID CRYSTAL; MICELLE; MICROEMULSION; NONHUMAN; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; TABERNAEMONTANA; TABERNAEMONTANA DIVARICATA; VISCOMETRY;

EID: 84884210522     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.05.005     Document Type: Article

References (52)

1. Alany, R.G., Tucker, I.G., Davies, N.M., Rades, T., 2001. Characterizing colloidal structures of pseudoternary phase diagrams formed by oil/water/amphiphile systems. Drug Dev. Ind. Pharm. 27, 31-38. (Pubitemid 32195358)
2. Asbill, C.S., Michniak, B.B., 2000. Percutaneous penetration enhancers: local versus transdermal activity. Pharm. Sci. Technol. Today 3, 36-41. (Pubitemid 30066493)
3. Beneteau, C., Khavinson, D., 2006. The isoperimetric inequality via approximation theory and free boundary problems. Comput. Meth. Funct. Theor. 6, 253.
4. Boonme, P., Krauel, K., Graf, A., Rades, T., Junyaprasert, V.B., 2006. Characterization of microemulsion structures in the pseudoternary phase diagram of isopropyl palmitate/water/Brij 97: 1-butanol. AAPS Pharm. Sci. Tech. 7, 99-104.
5. Brasnjevic, I., Steinbusch, H.W.M., Schmitz, C., Martinez-Martinez, P., 2009. Delivery of peptide and protein drugs over the blood-brain barrier. Prog. Neurobiol. 87, 212-251.
6. Brookmeyer, R., Johnson, E., Ziegler-Graham, K., Arrighi, H.M., 2007. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3, 186-191. (Pubitemid 46825511)
7. Chaiyana, W., Schripsema, J., Ingkaninan, K., Okonogi, S., 2013. 3′-R/S-hydroxyvoacamine, a potent acetylcholinesterase inhibitor from Tabernaemontana divaricata. Phytomedicine 20, 543-548.
8. Chattipakorn, S., Pongpanparadorn, A., Pratchayasakul, W., Pongchaidacha, A., Ingkaninan, K., Chattipakorn, N., 2007. Tabernaemontana divaricata extract inhibits neuronal acetylcholinesterase activity in rats. Journal of Ethnopharmacology 110, 61-68. (Pubitemid 46209570)
9. Cornwell, P.A., Barry, B.W., Bouwstra, J.A., Gooris, G.S., 1996. Modes of action of terpene penetration enhancers in human skin; differential scanning calorimetry, small-angle X-ray diffraction and enhancer uptake studies. Int. J. Pharm. 127, 9-26. (Pubitemid 26069150)
10. Danysz, W., Parsons, C.G., 2003. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int. J. Geriatr. Psychiatry 18, S23-S32. (Pubitemid 37150475)
11. El Maghraby, G.M., 2008. Transdermal delivery of hydrocortisone from eucalyptus oil microemulsion: effects of cosurfactants. Int. J. Pharm. 355, 285-292.
12. El Maghraby, G.M., 2010. Self-microemulsifying and microemulsion systems for transdermal delivery of indomethacin: effect of phase transition. Colloids Surf. B Biointerfaces 75, 595-600.
13. Ellman, G.L., Courtney, K.D., 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7, 88-90.
14. Ferderber, K., Hook, S., Rades, T., 2009. Phosphatidyl choline-based colloidal systems for dermal and transdermal drug delivery. J. Liposome Res. 19, 267-277.
15. Friberg, S.E., 1990. Micelles, microemulsions, liquid crystals, and the structure of stratum corneum lipids. J. Soc. Cosmet. Chem. 41, 155-171.
16. Ghochikyan, A., 2009. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol. Disord. Drug Targets 8, 128.
17. Greig, N.H., Utsuki, T., Yu, Q., Zhu, X., Holloway, H.W., Perry, T.A., Lee, B., Ingram, D.K., Lahiri, D.K., 2001. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr. Med. Res. Opin. 17, 159-165. (Pubitemid 34003119)
18. Ingkaninan, K., Changwijit, K., Suwanborirux, K., 2006. Vobasinyl-iboga bisindole alkaloids, potent acetylcholinesterase inhibitors from Tabernaemontana divaricata root. J. Pharm. Pharmacol. 58, 847-852. (Pubitemid 43836171)
19. Ingkaninan, K., Temkitthawon, P., Chuenchom, K., Yuyaem, T., Thongnoi, W., 2003. Screening for acetylcholinesterase inhibitory activity in plants used in Thai traditional rejuvenating and neurotonic remedies. J. Ethnopharmacol. 89, 261-264. (Pubitemid 37378200)
20. Johnson, N., Davis, T., Bosanquet, N., 2000. The epidemic of Alzheimer's disease: how can we manage the costs? Pharmacoeconomics 18, 215-223.
21. Kogan, A., Shalev, D.E., Raviv, U., Aserin, A., Garti, N., 2009. Formation and characterization of ordered bicontinuous microemulsions. J. Phys. Chem. B 113, 10669-10678.
22. Kokjohn, T.A., Roher, A.E., 2009. Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations and contributions. Alzheimers Dement 5, 340.
23. Krauel, K., Girvan, L., Hook, S., Rades, T., 2007. Characterisation of colloidal drug delivery systems from the naked eye to Cryo-FESEM. Micron 38, 796-803. (Pubitemid 47539895)
24. Lane, R.M., Potkin, S.G., Enz, A., 2005. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int. J. Neuropsychopharmacol. 9, 101-124. (Pubitemid 43068340)
25. Lefevre, G., Pommier, F., Sedek, G., Allison, M., Huang, H.L., Kiese, B., Ho, Y.Y., Appel-Dingemanse, S., 2008. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. J. Clin. Pharmacol. 48, 246-252.
26. Liu, H., Wang, Y., Lang, Y., Yao, H., Dong, Y., Li, S., 2009. Bicontinuous cyclosporin a loaded water-AOT/Tween 85-isopropylmyristate microemulsion: structural characterization and dermal pharmacokinetics in vivo. J. Pharm. Sci. 98, 1167-1176.
27. Lopes, L.B., Lopes, J.L.C., Oliveira, D.C.R., Thomazini, J.A., Garcia, M.T.J., Fantini, M.C.A., Collett, J.H., Bentley, M., 2006. Liquid crystalline phases of monoolein and water for topical delivery of cyclosporin A: characterization and study of in vitro and in vivo delivery. Eur. J. Pharm. Biopharm. 63, 146-155. (Pubitemid 43776220)
28. Martin, R., Farlow, J.L.C., 2007. Effective pharmacologic management of Alzheimer's disease. Am. J. Med. 120, 388-397.
29. Megrab, N.A., Williams, A.C., Barry, B.W., 1995. Oestradiol permeation across human skin, silastic and snake skin membranes: the effects of ethanol/water co-solvent systems. Int. J. Pharm. 116, 101-112.
30. Morimoto, H., Wada, Y., Seki, T., Sugibayashi, K., 2002. In vitro skin permeation of morphine hydrochloride during the finite application of penetration-enhancing system containing water, ethanol and L-menthol. Biol. Pharm. Bull. 25, 134-136.
31. Mukherjee, P.K., Kumar, V., Mal, M., Houghton, P.J., 2007. Acetylcholinesterase inhibitors from plants. Phytomedicine 14, 289-300. (Pubitemid 46415622)
32. Nakamura, N., Tagawa, T., Kihara, K., Tobita, I., Kunieda, H., 1997. Phase transition between microemulsion and lamellar liquid crystal. Langmuir 13, 2001-2006. (Pubitemid 127651070)
33. Nakdook, W., Khongsombat, O., Taepavarapruk, P., Taepavarapruk, N., Ingkaninan, K., 2010. The effects of Tabernaemontana divaricata root extract on amyloid [beta]-peptide 25-35 peptides induced cognitive deficits in mice. J. Ethnopharmacol. 130, 122-126.
34. Podlogar, F., Gaperlin, M., Tomi, M., Jamnik, A., Roga, M., 2004. Structural characterisation of water-Tween 40o/Imwitor 308o-isopropyl myristate microemulsions using different experimental methods. Int. J. Pharm. 276, 115-128. (Pubitemid 38548840)
35. Savić, S.D., Savić, M.M., Vesić, S.A., Vuleta, G.M., Müller-Goymann, C.C., 2006. Vehicles based on a sugar surfactant: colloidal structure and its impact on in vitro/in vivo hydrocortisone permeation. Int. J. Pharm. 320, 86-95. (Pubitemid 44128709)
36. Schwarz, J.S., Weisspapir, M.R., Friedman, D.I., 1995. Enhanced transdermal delivery of diazepam by submicron emulsion (SME) creams. Pharm. Res. 12, 687-692.
37. Schwuger, M.J., Stickdorn, K., Schomaecker, R., 1995. Microemulsions in technical processes. Chem. Rev. 95, 849-864.
38. Sheth, N.V., Freeman, D.J., Higuchi, W.I., Spruance, S.L., 1986. The influence of Azone, propylene glycol and polyethylene glycol on in vitro skin penetration of trifluorothymidine. Int. J. Pharm. 28, 201-209. (Pubitemid 16187098)
39. Sommer, B., 2002. Alzheimer's disease and the amyloid cascade hypothesis: ten years on. Curr. Opin. Pharmacol. 2, 87-92.
40. Szekely, C.A., Breitner, J.C.S., Zandi, P.P., 2007. Prevention of Alzheimer's disease. Int. Rev. Psychiatry 19, 693-706. (Pubitemid 351185554)
41. Vaddi, H., Ho, P., Chan, S., 2002. Terpenes in propylene glycol as skin penetration enhancers: permeation and partition of haloperidol, fourier transform infrared spectroscopy, and differential scanning calorimetry. J. Pharm. Sci. 91, 1639-1651. (Pubitemid 34680226)
42. Vassar, R., 2002. [beta]-Secretase (BACE) as a drug target for Alzheimer's disease. Adv. Drug Deliv. Rev. 54, 1589-1602. (Pubitemid 35346833)
43. Walker, R.B., Smith, E.W., 1996. The role of percutaneous penetration enhancers. Adv. Drug Deliv. Rev. 18, 295-301. (Pubitemid 26063305)
44. Wentrup, A., Oertel, W.H., Dodel, R., 2008. Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease. Drug. Des. Dev. Ther. 2, 245-254.
45. Williams, A.C., Barry, B.W., 1991a. Terpenes and the lipid-protein- partitioning theory of skin penetration enhancement. Pharm. Res. 8, 17-24.
46. Williams, A.C., Barry, B.W., 1991b. The enhancement index concept applied to terpene penetration enhancers for human skin and model lipophilic (oestradiol) and hydrophilic (5-fluorouracil) drugs. Int. J. Pharm. 74, 157-168.
47. Williams, A.C., Barry, B.W., 2004. Penetration enhancers. Adv. Drug Deliv. Rev. 56, 603-618. (Pubitemid 38326936)
48. Winblad, B.B., Cummings, J., Andreasen, N., Grossberg, G., Onofrj, M., Sadowsky, C., Zechner, S., Nagal, J., Lane, R., 2007. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int. J. Geriatr. Psychiatry 22, 456-467. (Pubitemid 46831690)
49. Yaghmur, A., Aserin, A., Garti, N., 2002. Phase behavior of microemulsions based on food-grade nonionic surfactants: effect of polyols and short-chain alcohols. Colloid Surf. A 209, 71-81. (Pubitemid 34808799)
50. Yoshioka, T., Sternberg, B., Florence, A.T., 1994. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60, and 80) and a sorbitan triester (Span 85). Int. J. Pharm. 105, 1-6. (Pubitemid 24087666)
51. Zapf, A., Beck, R., Platz, G., Hoffmann, H., 2003. Calcium surfactants: a review. Adv. Colloid. Interface Sci. 100, 349-380.
52. Zhang, J., Michniak-Kohn, B., 2011. Investigation of microemulsion microstructures and their relationship to transdermal permeation of model drugs: Ketoprofen, lidocaine, and caffeine. Int. J. Pharm. 421, 34-44.